Aug. 14 at 7:02 PM
$QNCX Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027
Closed private placement financing, receiving
$115 million in upfront gross proceeds, with potential for up to an additional
$83 million upon exercise of warrants (including warrants issued to former Orphai stockholders)
Cash and cash equivalents of
$116 million as of June 30, 2026, expected to fund operations through the end of 2028
